Eptazocine
Opioid analgesic
- None
- In general: ℞ (Prescription only)
- (1S,6S)-1,4-dimethyl-2,3,4,5,6,7-hexahydro-1H-1,6-methano-4-benzazonin-10-ol
- 72522-13-5
72150-17-5 (bromide)
- 3042090
- 2305268
- 2208ZLI77S
- ChEMBL70566
- Interactive image
- Oc1ccc2c(c1)[C@@]3(CCN(C[C@H](C2)C3)C)C
InChI
- InChI=1S/C15H21NO/c1-15-5-6-16(2)10-11(9-15)7-12-3-4-13(17)8-14(12)15/h3-4,8,11,17H,5-7,9-10H2,1-2H3/t11-,15-/m1/s1
- Key:ZOWQTJXNFTWSCS-IAQYHMDHSA-N
Eptazocine (Sedapain) is an opioid analgesic which was introduced in Japan by Morishita in 1987.[1][2][3][4] It acts as a mixed κ-opioid receptor agonist and μ-opioid receptor antagonist.[4][5][6]
See also
References
- ^ Index nominum 2000: international drug directory. Taylor & Francis US. 2000. p. 396. ISBN 978-3-88763-075-1. Retrieved 29 November 2011.
- ^ American Chemical Society. Division of Medicinal Chemistry (1990). "Cumulative NCE Introduction index, 1983-189, by Indication". In Bristol JA (ed.). Annual Reports in Medicinal Chemistry. Academic Press. p. 381. ISBN 978-0-12-040525-1. Retrieved 29 November 2011.
- ^ Nabeshima T, Matsuno K, Kamei H, Kameyama T (May 1985). "The interaction of eptazocine, a novel analgesic, with opioid receptors". Research Communications in Chemical Pathology and Pharmacology. 48 (2): 173–181. PMID 2992058.
- ^ a b Nagase H, Fujii H (21 January 2011). "Synthesis of Novel Basic Skeletons Derived from Naltrexone". In Nagase H, Calderon SN (eds.). Chemistry of Opioids. Springer. p. 280. ISBN 978-3-642-18106-1. Retrieved 29 November 2011.
- ^ Tamura T, Ogawa J, Taniguchi T, Waki I (January 1990). "[Preferential action of eptazocine, a novel analgesic, with opioid receptors in isolated guinea pig ileum and mouse vas deferens preparations]". Nihon Yakurigaku Zasshi. Folia Pharmacologica Japonica (in Japanese). 95 (1): 41–46. doi:10.1254/fpj.95.1_41. PMID 2154395.
- ^ Morton IK, Hall JM (1999). Concise dictionary of pharmacological agents: properties and synonyms. Springer. p. 113. ISBN 978-0-7514-0499-9. Retrieved 29 November 2011.
- v
- t
- e
modulators
| Calcium blockers |
|
|---|---|
| Sodium blockers |
|
| Potassium openers |
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
